These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3653699)

  • 1. Dopamine action and disorders of neurotransmitter balance.
    Birkmayer W; Birkmayer JD
    Gerontology; 1987; 33(3-4):168-71. PubMed ID: 3653699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1974; 35(2):93-116. PubMed ID: 4844103
    [No Abstract]   [Full Text] [Related]  

  • 3. Some remarks concerning the possible role of brain monoamines (dopamine, noradrenaline, serotonin) in mental disorders.
    Hornykiewicz O
    J Psychiatr Res; 1974; 11():249-53. PubMed ID: 4282386
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.
    Scatton B; Javoy-Agid F; Rouquier L; Dubois B; Agid Y
    Brain Res; 1983 Sep; 275(2):321-8. PubMed ID: 6626985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.
    Fahn S; Libsch LR; Cutler RW
    J Neurol Sci; 1971 Dec; 14(4):427-55. PubMed ID: 5125758
    [No Abstract]   [Full Text] [Related]  

  • 6. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract]   [Full Text] [Related]  

  • 8. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1972; 33(2):163-78. PubMed ID: 4643007
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 10. Experimentally induced parkinsonism.
    Poirier LJ; Sourkes TL
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():416-33. PubMed ID: 4403656
    [No Abstract]   [Full Text] [Related]  

  • 11. Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V
    Arch Neurol; 1973 Feb; 28(2):107-10. PubMed ID: 4683147
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical implications of monoamine oxidase inhibition.
    Pare CM
    Adv Biochem Psychopharmacol; 1972; 5():441-4. PubMed ID: 5054212
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of chronically administered L-dopa in normal and lesioned cats.
    Langelier P; Roberge AG; Boucher R; Poirier LJ
    J Pharmacol Exp Ther; 1973 Oct; 187(1):15-26. PubMed ID: 4746324
    [No Abstract]   [Full Text] [Related]  

  • 14. Brain amine concentrations after monoamine oxidase inhibitor administration.
    Jones AB; Pare CM; Nicholson WJ; Price K; Stacey RS
    Br Med J; 1972 Jan; 1(5791):17-9. PubMed ID: 5008339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of frontal pole ablation on biogenic amine levels in the brain.
    Nielson HC
    Exp Neurol; 1966 Aug; 15(4):484-9. PubMed ID: 5911101
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The probenecid test. Evaluation in clinical medicine of cerebral metabolism of serotonin and dopamine].
    Véron JP; Mérienne L
    Nouv Presse Med; 1972 Feb; 1(8):537-9. PubMed ID: 4258943
    [No Abstract]   [Full Text] [Related]  

  • 18. Toxic delirium after L-dopa medication.
    Birkmayer W
    J Neural Transm Suppl; 1978; (14):163-6. PubMed ID: 290736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
    Stahl SM
    CNS Spectr; 2016 Oct; 21(5):355-359. PubMed ID: 27686027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.